• The number of prevalent cases of uterine fibroids in the countries under study will remain relatively stable over the 20-year forecast period.
  • Of the countries considered in this analysis, the United States has the highest prevalence of uterine fibroids: 38%.
  • Most women with uterine fibroids are unaware that they have them; only 39% of women aged 20-54 living with the disease have been diagnosed.

Table of contents

  • Uterine Fibroids - Epidemiology - Mature Markets
    • Introduction
      • Key Findings
        • Overview
          • Total Prevalence of Uterine Fibroids per 100 Women Aged 20-54 in 2020 and 2040
          • Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Uterine Fibroids over the Next 20 Years
          • Analysis of Total Prevalent Cases of Uterine Fibroids by Diagnosed and Drug-Treated Status
      • Epidemiology Data
      • Methods
        • Total Prevalent Cases
        • Diagnosed Prevalent Cases of Uterine Fibroids
        • Diagnosed Incident Cases
        • Drug-Treated Prevalent Cases of Uterine Fibroids
        • Lifetime DALYs Gained
      • Reference Materials
        • Literature Review
          • Studies Included in the Analysis of Uterine Fibroids
          • Studies Excluded from the Analysis of Uterine Fibroids
        • Risk/Protective Factors
          • Risk/Protective Factors for Uterine Fibroids
        • Bibliography

    Author(s): Julie Davis; Oliver Blandy, M.Sc.

    Julie Davis, M.P.H., is an associate epidemiologist at DRG, part of Clarivate. Prior to joining DRG, she was a research assistant at Tufts Medical Center, where she studied accelerated osteoarthritis and other rheumatic diseases. She also has experience working with data related to zoonotic disease transmission and excess mortality in Puerto Rico stemming from Hurricane Maria. She was part of the Health Emergencies team at the Pan American Health Organization, working on disaster preparedness and communicable disease risk assessments. Ms. Davis received her M.P.H. in global health epidemiology and disease control from George Washington University and holds a bachelor’s degree in health sciences from James Madison University.

    Oliver Blandy, M.Sc., is a senior epidemiologist at DRG, part of Clarivate. Before joining DRG, Oliver worked as a research assistant for Imperial College London, where he was the lead for several studies within an NIRH-funded research group investigating healthcare-associated infections and antimicrobial resistance. He holds an M.Sc. from the University of Bristol, where he specialized in nutrition, physical activity, and public health. He also holds a B.Sc. in chemistry and a postgraduate certificate in education, both from the University of Bristol.

    Related Reports

    Uterine Fibroids - Landscape & Forecast - Disease Landscape & Forecast

    Uterine fibroids are characterized by heavy menstrual bleeding (menorrhagia), pelvic pressure due to increased uterine bulk, abdominal and back pain, and fertility issues. Disease management may in...

    View Details